Geron Corporation Insider Trading

GERN

Last 12 months

Insiders sold 19K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. EVP, Chief Financial Officer Michelle Robertson sold 19K on Feb 18, 36% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2025.

Net open-market

−19K

0 buys · 1 sale

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

May 2025

May 9, 2025

Get an email when GERN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Feb 18	Michelle Robertson EVP, Chief Financial Officer	SoldNo plan	9,855	$1.94	19K	36%	Form 4
May 9, 2025	V Bryan Lawlis Director	Bought	13,300	$1.18	16K	New	Form 4
Feb 27, 2025	Scott Alan Samuels EVP, Chief Legal Officer	Bought	15,000	$1.61	24K	128%	Form 4
Feb 27, 2025	John A Scarlett Chairman, President and CEO	Bought	12,500	$1.77	22K	10%	Form 4
Feb 27, 2025	James Ziegler EVP, Chief Commercial Officer	Bought	100,000	$1.60	160K	New	Form 4

Feb 18No plan
Michelle Robertson
EVP, Chief Financial Officer · sold 9,855 at $1.94
19K
36% of stake
May 9, 2025
V Bryan Lawlis
Director · bought 13,300 at $1.18
16K
New position
Feb 27, 2025
Scott Alan Samuels
EVP, Chief Legal Officer · bought 15,000 at $1.61
24K
128% of stake
Feb 27, 2025
John A Scarlett
Chairman, President and CEO · bought 12,500 at $1.77
22K
10% of stake
Feb 27, 2025
James Ziegler
EVP, Chief Commercial Officer · bought 100,000 at $1.60
160K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch GERN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with GERN

CompareIntrinsic value

INVAInnoviva Inc.

$21.26+1.58%56

CNTACentessa Pharmaceuticals plc

No recent price10

IDYAIdeaya Biosciences Inc.

$32.36+3.29%40

SYRESpyre Therapeutics, Inc.

$99.24-0.03%10

PCRXPacira BioSciences Inc.

$36.40+0.03%58

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

LPCNLipocine Inc.

$1.44-1.37%40

VRTXVertex Pharmaceuticals Incorporated

$549.04+3.44%47

Held by ETFs

GERN is in 26 US ETFs. The largest of them, with GERN's weight in each:

Spot a number that looks wrong? Check it in GERN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GERN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.